CA2661329C - Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant) - Google Patents

Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant) Download PDF

Info

Publication number
CA2661329C
CA2661329C CA2661329A CA2661329A CA2661329C CA 2661329 C CA2661329 C CA 2661329C CA 2661329 A CA2661329 A CA 2661329A CA 2661329 A CA2661329 A CA 2661329A CA 2661329 C CA2661329 C CA 2661329C
Authority
CA
Canada
Prior art keywords
insulin
acid
composition
diabetes
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2661329A
Other languages
English (en)
French (fr)
Other versions
CA2661329A1 (fr
Inventor
Claude Andary
Gerard Ribes
Didier Tousch
Jacqueline Azay-Milhau
Anne-Dominique Lajoix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Montpellier
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Montpellier filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2661329A1 publication Critical patent/CA2661329A1/fr
Application granted granted Critical
Publication of CA2661329C publication Critical patent/CA2661329C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2661329A 2006-08-18 2007-08-17 Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant) Expired - Fee Related CA2661329C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0607382A FR2904935A1 (fr) 2006-08-18 2006-08-18 Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant).
FR06/07382 2006-08-18
PCT/EP2007/058580 WO2008022974A2 (fr) 2006-08-18 2007-08-17 Composition antidiabetique contenant de l'acide chicorique et/ou l'un de ses metabolites

Publications (2)

Publication Number Publication Date
CA2661329A1 CA2661329A1 (fr) 2008-02-28
CA2661329C true CA2661329C (fr) 2016-01-12

Family

ID=37836752

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2661329A Expired - Fee Related CA2661329C (fr) 2006-08-18 2007-08-17 Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant)

Country Status (7)

Country Link
US (1) US8404746B2 (enExample)
EP (1) EP2056802B1 (enExample)
JP (1) JP5242567B2 (enExample)
CA (1) CA2661329C (enExample)
ES (1) ES2410205T3 (enExample)
FR (1) FR2904935A1 (enExample)
WO (1) WO2008022974A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210505A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
EP2210504A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising chicoric acid and/or derivatives thereof
JP2013530995A (ja) * 2010-06-30 2013-08-01 ネステク ソシエテ アノニム 皮膚の色素沈着を調節するための、栄養補助食品におけるチコリ酸及び誘導体の使用
JP6346564B2 (ja) * 2011-11-18 2018-06-20 ナチュレックス チコリ抽出物を含む組成物
US20140045937A1 (en) * 2012-08-08 2014-02-13 Oculus Innovative Sciences, Inc. Methods of treating polycystic ovarian syndrome using chlorogenic acid
WO2014048888A1 (en) * 2012-09-28 2014-04-03 Nestec S.A. Dihydroferulic acid and/or dihydrocaffeic acid for use in the treatment of metabolic diseases
EP2968426A4 (en) * 2013-03-12 2016-10-12 Hmi Medical Innovations Llc PLANT EXTRACTS WITH ANTIDIBLE EFFECT AND OTHER BENEFITS
EP2848286A1 (en) * 2013-09-12 2015-03-18 DSM IP Assets B.V. Cosmetic composition comprising chicoric acid
DK3089707T3 (da) * 2013-12-30 2021-10-11 New York Stem Cell Found Inc Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
FR3017510B1 (fr) 2014-02-19 2017-04-21 Inst Nat De La Rech Agronomique - Inra Composition phytosanitaire
US9259410B2 (en) 2014-04-08 2016-02-16 Oculus Innovative Sciences, Inc. Methods of treating polycystic ovarian syndrome using chlorogenic acid and inositol
JP6981685B2 (ja) * 2014-10-21 2021-12-17 丸善製薬株式会社 皮膚化粧料、頭髪化粧料および飲食品
FR3042411B1 (fr) * 2015-10-20 2019-07-12 Valbiotis Composition comprenant un melange de molecules particulieres et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
DE102015118318B4 (de) 2015-10-27 2018-05-03 Karl Leibinger Medizintechnik Gmbh & Co. Kg Automatisierte Generierung von Knochenbehandlungsmitteln
JP6700029B2 (ja) * 2015-12-04 2020-05-27 国立大学法人神戸大学 糖取り込み促進剤
DE102017206827A1 (de) * 2017-04-24 2018-10-25 Roman Gehre Gewinnung und Nutzung von Polyphenolen, insbesondere Cichoriensäure, aus Pflanzen der Gattung Posidonia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1949822A1 (de) * 1969-10-02 1971-04-15 Ferdinand Sedlacek Verfahren zur Herstellung eines Mittels zwecks Normalisierung des Blutzuckergehaltes
JPS6140763A (ja) 1984-08-02 1986-02-27 Osaka Chem Lab 抗肥満食品
JPS61171418A (ja) * 1985-01-23 1986-08-02 Wakunaga Seiyaku Kk 抗糖尿病剤
FR2638967B1 (fr) * 1988-11-17 1993-10-22 Andary Claude Derives de l'acide cafeique pour leur application en tant qu'analgesiques
CN1032403C (zh) * 1992-11-19 1996-07-31 秦元贵 中药奇可力制剂及其制备方法
JP2002524505A (ja) * 1998-09-15 2002-08-06 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 高血中脂質濃度に因る疾患の予防または治療のための、ケイ皮酸誘導体を含む組成物
GB9903216D0 (en) * 1999-02-13 1999-04-07 Zylepsis Ltd Preservative compounds,compositions and methods of making and using the same
US7056539B2 (en) * 1999-03-12 2006-06-06 Vladimir Leko Process and product extracted from herbal composition useful in controlling diabetes mellitus type II
CH694360A5 (de) * 2000-07-21 2004-12-15 Bioforce Ag Extraktion von Wirkstoffen aus Pflanzen.
JP3548102B2 (ja) * 2000-08-07 2004-07-28 花王株式会社 高血圧症予防・治療剤
JP2005314435A (ja) * 2000-08-30 2005-11-10 Eijiro Tagashira 循環器疾患治療剤および健康食品
JP4361228B2 (ja) * 2001-01-12 2009-11-11 和歌山県 体重増加抑制剤
FR2820738B1 (fr) * 2001-02-15 2003-05-16 Agronomique Inst Nat Rech Procede d'extraction, de fractionnement et de purification de composes polyphenoliques issus d'ecarts de triage de vegetaux frais utilisant une resine a haut rendement d'adsorption et d'elution
JP2002363075A (ja) * 2001-06-05 2002-12-18 Kao Corp 高血圧症予防・治療剤
JP2003116486A (ja) * 2001-08-09 2003-04-22 Meiji Milk Prod Co Ltd 食後の血糖上昇抑制作用を有する食品組成物
FR2830251A1 (fr) * 2001-10-01 2003-04-04 Univ Claude Bernard Lyon Procede de synthese de l'acide chicorique
EP1559421B1 (en) * 2002-11-06 2016-07-27 Kao Corporation Blood circulation promoting agent
HRP20030816B1 (hr) * 2003-10-10 2012-05-31 Leko Vlado Biljni pripravak u obliku kapsula kao pomoćni lijek za dijabetes mellitus tipa (i) i (ii)
AU2005259864A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders

Also Published As

Publication number Publication date
JP5242567B2 (ja) 2013-07-24
FR2904935A1 (fr) 2008-02-22
EP2056802A2 (fr) 2009-05-13
JP2010501023A (ja) 2010-01-14
US8404746B2 (en) 2013-03-26
WO2008022974A3 (fr) 2008-12-04
ES2410205T3 (es) 2013-07-01
CA2661329A1 (fr) 2008-02-28
EP2056802B1 (fr) 2013-03-13
WO2008022974A2 (fr) 2008-02-28
US20110015140A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
CA2661329C (fr) Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant)
Chung et al. Anti-diabetic effects of lemon balm (Melissa officinalis) essential oil on glucose-and lipid-regulating enzymes in type 2 diabetic mice
US6541522B2 (en) Methods of using compositions containing hypotriglyceridemically active stilbenoids
Gupta et al. Nutritional and therapeutic values of Stevia rebaudiana: A review
Le et al. The petroleum ether extract of Nigella sativa exerts lipid-lowering and insulin-sensitizing actions in the rat
Bidie et al. Activités antioxydantes de dix plantes medicinales de la pharmacopée ivoirienne.
Atchibri et al. Screening for antidiabetic activity and phytochemical constituents of common bean (Phaseolus vulgaris L.) seeds
US10857193B2 (en) Extract formulation of Opuntia ficus indica
US20080003312A1 (en) Method of improving fat metabolism
MXPA04011089A (es) Composiciones bioactivas de similla de fenogreco y metodos para extraerla misma.
JP2008297209A (ja) 脂質代謝改善組成物
Ani et al. Anti-diabetic, anti-hyperlipidemic and hepatoprotective potential of shaddock (Citrus maxima) peel extract.
KR100828069B1 (ko) 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,지방간의 예방 또는 치료용 조성물
Kulandaivel et al. Antihyperglycemic activity of Trichosanthes tricuspidata root extract
US20020058708A1 (en) Compositions containing hypotriglyceridemically active stilbenoids
EP3675960B1 (fr) Composition pour son utilisation dans le traitement et/ou la prevention de l'infertilite
EP2819635B1 (fr) Produit de combinaison pour le traitement du surpoids et/ou l'amélioration de la silhouette
JP2013040108A (ja) 抗肥満剤
JP2005336069A (ja) 抗糖尿病用組成物
Kumar et al. Influence of Helicteres isora bark extracts on plasma and tissue glycoprotein components in streptozotocin diabetic rats
Pyne et al. Antidiabetic efficacy of sea fish oil in ameliorating hyperglycaemia by enhancing FFAR1, GLP-1 and inhibiting DPP-4 signalling in the pancreatic tissues of high lipid diet and streptozotocin-induced type 2 diabetic rats
KR100657017B1 (ko) 도라지 추출물을 함유하는 ｌ-ｆａｂｐ 증강제 및 그 정제방법
KR20120136285A (ko) 지방 세포화 억제 활성을 갖는 프리형 및 에스테르형 캅산틴을 포함하는 항비만용 기능성 식품 및 약학 조성물
US20070269540A1 (en) Fat metabolism improving agent
EP2197437A1 (fr) Utilisation de l'oleocanthal pour le traitement des troubles du metabolisme lipidique

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180817